NOV 28, 2015 6:11 AM PST

A Combination of Drugs and Immunotherapy To Treat Breast Cancer

WRITTEN BY: Kara Marker
The American Cancer Society predicts that over 40,000 women will die from breast cancer this year, and that's just in the United States. As motivated as ever, scientists from the University of Basel have developed a novel treatment plan to target breast cancer. 

With their results published in Science Translational Medicine, the team from Switzerland successfully created an "antibody-drug conjugate" (ADC) to pair with immunotherapy to attack cancerous cells. The ADC stimulates the immune system to bind to and kill tumor cells as they grow. 

The basis of the ADC mechanism comes from an observation of breast cell growth factors. About one-fifth of breast cancer patients show increased levels of human growth factor receptor 2 (HER2) on their tumor cell surfaces (breastcancer.org). Normal breast cell growth is harmless, but when too many HER2 genes are stimulating growth, cancer occurs. The ADC developed by the scientists from the University of Basel blocks the action of these malfunctioning receptors while simultaneously releasing cytotoxic chemicals that enter the tumor cell and instigate cell death.

In a study of mouse breast cancer models, the team combined ADC administration with immunotherapy treatments. By administering complementary antibodies to activate T lymphocytes, immunotherapy helps "reroute" the body's natural "immunoregulatory checkpoints" to ensure the right immune cells are being activated to fight the cancer. Without pairing immunotherapy with ADC treatment, T cell activation would not be as helpful. 

Combination therapy is a bright, new perspective for breast cancer treatment, and doctors like lead author Philipp Muller believe that "antibody-drug conjugates are suitable for use in a combination therapy."

Watch the following video to hear more about ADCs in detail.
Source: University of Basel
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
FEB 13, 2020
Immunology
FEB 13, 2020
Protein that suppresses immune system linked to lupus
  A study published in Human Immunology has described, for the first time, a link between an immunosuppressive prot ...
FEB 23, 2020
Immunology
FEB 23, 2020
New discovery could help preterm babies breathe easy
Babies born more than three weeks before full term are met with complicated and often life-threatening health challenges ...
MAR 20, 2020
Health & Medicine
MAR 20, 2020
Why Does COVID-19 Kill So Many Older People?
Since early statistics began to emerge from China, it seemed that COVID-19 tended to affect older people more than young ...
APR 13, 2020
Drug Discovery & Development
APR 13, 2020
Are COVID-19 Antibody Tests a Back-to-Work Pass?
Although treatments and vaccines against COVID-19 may still be months away, antibody tests are becoming more widespread. ...
APR 11, 2020
Drug Discovery & Development
APR 11, 2020
Promising Experimental Anti-Malarial Drug
At St. Jude Children’s Research Hospital, researchers discovered a fast-acting anti-malarial compound with promisi ...
MAY 06, 2020
Drug Discovery & Development
MAY 06, 2020
Breakthrough in Antibody Treatment for COVID-19
Israeli scientists have announced significant progress in isolating an antibody that may be effective in treating those ...
Loading Comments...